Vistagen Therapeutics (VTGN) Competitors $2.50 +0.25 (+11.11%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VTGN vs. ELDN, URGN, RZLT, AVIR, CMRX, ATYR, MRSN, HRTX, FULC, and ACBShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), Chimerix (CMRX), Atyr PHARMA (ATYR), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Fulcrum Therapeutics (FULC), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Vistagen Therapeutics vs. Eledon Pharmaceuticals UroGen Pharma Rezolute Atea Pharmaceuticals Chimerix Atyr PHARMA Mersana Therapeutics Heron Therapeutics Fulcrum Therapeutics Aurora Cannabis Eledon Pharmaceuticals (NASDAQ:ELDN) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership. Which has more risk & volatility, ELDN or VTGN? Eledon Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Is ELDN or VTGN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -189.99% -28.17% Vistagen Therapeutics -4,521.71%-36.35%-33.62% Which has higher earnings and valuation, ELDN or VTGN? Vistagen Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$116.54M-$2.01-2.17Vistagen Therapeutics$876K79.46-$29.36M-$1.24-2.02 Do institutionals & insiders believe in ELDN or VTGN? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate ELDN or VTGN? Eledon Pharmaceuticals currently has a consensus target price of $16.00, suggesting a potential upside of 266.97%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the MarketBeat Community believe in ELDN or VTGN? Vistagen Therapeutics received 255 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 72.31% of users gave Vistagen Therapeutics an outperform vote. CompanyUnderperformOutperformEledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Does the media refer more to ELDN or VTGN? In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Vistagen Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 1.86 beat Vistagen Therapeutics' score of 0.76 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eledon Pharmaceuticals Very Positive Vistagen Therapeutics Positive SummaryVistagen Therapeutics beats Eledon Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.61M$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-2.0210.55135.2017.16Price / Sales79.46194.011,120.31115.67Price / CashN/A57.1640.5837.88Price / Book0.595.104.754.78Net Income-$29.36M$151.51M$118.50M$225.60M7 Day Performance2.88%-2.13%-1.85%-1.21%1 Month Performance-1.57%-3.14%11.27%3.09%1 Year Performance-50.98%11.54%29.92%16.48% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics0.9865 of 5 stars$2.50+11.1%N/A-50.3%$69.61M$876,000.00-2.0240High Trading VolumeELDNEledon Pharmaceuticals2.9286 of 5 stars$4.51+3.0%$16.00+254.8%+196.6%$269.43MN/A-2.3310Positive NewsHigh Trading VolumeURGNUroGen Pharma3.8718 of 5 stars$11.44+0.8%$43.70+282.0%-28.4%$268.27M$82.71M-3.60200RZLTRezolute3.1807 of 5 stars$4.60+0.2%$24.13+424.5%+387.8%$266.54MN/A-3.6140AVIRAtea Pharmaceuticals3.2604 of 5 stars$3.15+7.5%$6.88+118.4%+5.6%$266.06M$351.37M-1.5370High Trading VolumeCMRXChimerix4.34 of 5 stars$2.92-1.0%$8.50+191.1%+218.1%$262.63M$320,000.00-3.1472ATYRAtyr PHARMA2.4827 of 5 stars$3.11+1.6%$19.25+519.0%N/A$261.06M$235,000.00-3.2656News CoverageMRSNMersana Therapeutics4.4154 of 5 stars$2.06-4.2%$6.00+191.3%-16.2%$254.47M$36.85M-3.52150Positive NewsHRTXHeron Therapeutics3.956 of 5 stars$1.67+4.4%$5.67+239.3%-2.5%$254.00M$137.74M-8.89300Analyst DowngradeFULCFulcrum Therapeutics1.716 of 5 stars$4.43+11.9%$9.33+110.7%-22.6%$238.95M$80.87M-13.68100Positive NewsACBAurora Cannabis0.0906 of 5 stars$4.30-0.2%N/A-8.4%$235.81M$200.35M-5.671,073Analyst RevisionNews Coverage Related Companies and Tools Related Companies ELDN Alternatives URGN Alternatives RZLT Alternatives AVIR Alternatives CMRX Alternatives ATYR Alternatives MRSN Alternatives HRTX Alternatives FULC Alternatives ACB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTGN Stock Alerts